|
|
| | Glu-Urea-Lys(Ahx-HYNIC) Basic information |
| Product Name: | Glu-Urea-Lys(Ahx-HYNIC) | | Synonyms: | Glu-Urea-Lys(Ahx-HYNIC);(14S,18S)-1-(6-Hydrazineylpyridin-3-yl)-1,8,16-trioxo-2,9,15,17-tetraazaicosane-14,18,20-tricarboxylic acid;Retatrutide Intermediate | | CAS: | 2213408-17-2 | | MF: | C24H37N7O9 | | MW: | 567.59 | | EINECS: | | | Product Categories: | | | Mol File: | 2213408-17-2.mol |  |
| | Glu-Urea-Lys(Ahx-HYNIC) Chemical Properties |
| density | 1.45±0.1 g/cm3(Predicted) | | pka | 3.78±0.10(Predicted) | | form | Solid | | color | White to off-white | | Sequence | Glu-Urea-Lys(Ahx-HYNIC) |
| | Glu-Urea-Lys(Ahx-HYNIC) Usage And Synthesis |
| Uses | HYNIC-PSMA is a ligand for molecular imaging of tumors. Hynic-psma consists of two components: HYNIC (6-hydrazinonicotinamide) and PSMA (Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules, such as 188Re-HYNIC-PSMA. PSMA is a membrane antigen that is specifically expressed on the surface of prostate cancer cells. HYNIC-PSMA can be used in prostate cancer research[1]. HYNIC-PSMA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs). | | References | [1] Hadisi M, et al. Preclinical evaluation of 188 Re-HYNIC-PSMA as a novel therapeutic agent[J]. Journal of Radioanalytical and Nuclear Chemistry, 2022, 331(2): 841-849. |
| | Glu-Urea-Lys(Ahx-HYNIC) Preparation Products And Raw materials |
|